

CANNON BUILDING  
861 SILVER LAKE BLVD., SUITE 203  
DOVER, DELAWARE 19904-2467

**STATE OF DELAWARE**  
**BOARD OF PHARMACY**

11/30/15 cm  
TELEPHONE: (302) 744-4500  
FAX: (302) 739-2711  
WEBSITE: [DPR.DELAWARE.GOV](http://DPR.DELAWARE.GOV)  
EMAIL: [customerservice.dpr@state.de.us](mailto:customerservice.dpr@state.de.us)



**PUBLIC MEETING NOTICE: BOARD OF PHARMACY – Patient Safety Committee Meeting**

**DATE AND TIME: Wednesday, November 18, 2015 8:30 am**

**PLACE:** Conference Room A, 2<sup>nd</sup> Floor Cannon Building  
861 Silver Lake Blvd., Dover, DE 19904

**APPROVED:**

**MEMBERS PRESENT**

Michelle McCreary – Chair  
Hooshang Shanehsaz, R.Ph.  
Susan Esposito, R.Ph.  
Joli Martini, R.Ph.  
Tejal Patel, PharmD

**MEMBERS ABSENT**

Kim Robbins, R.Ph.  
Kenneth Sellers  
Jay Patel

**DIVISION STAFF/DEPUTY ATTORNEY GENERAL PRESENT**

David Dryden, Executive Secretary  
Eileen Kelly, Deputy Attorney General  
Christine Mast, Administrative Specialist III

**CALL TO ORDER**

Ms. McCreary called the meeting to order at 8:46 am.

**MEETING MINUTES REVIEW**

A motion to approve the minutes for October 21, 2015 was made by Ms. Martini, seconded by Ms. Patel. The motion unanimously carried.

**OLD BUSINESS**

Mr. Shanehsaz stated that continued work within various health organizations regarding the Prescription Monitoring Program has continued to move in the direction of including all prescribed medications. This will provide practitioners a database that will allow treatment based on all medications prescribed by all practitioners. Thus providing better care and prescribing practices.

Mr. Dryden stated that the Division of Professional Regulation in conjunction with the PMP administrator continue to research the requirements to allow all prescribed medications to be included in the PMP database. Inclusion of all drugs will likely take more time to finalize than previously anticipated due to statutory changes needed to support the effort.

The committee request removing this agenda item until discussion of this subject is brought back to the Board of Pharmacy in a more finalized state.

The committee continued discussing appropriate disciplinary action resulting from violating regulations. The committee determined that public safety is the primary issue surrounding the changes therefore, the minimum per occurrence rate should be increased significantly per occurrence for noncompliance of the Boards regulations. Ms. Kelly explained that the Legislative Committee is also reviewing the substantially similar crimes listing as well as the minimum fines and violations. The committee agreed to remove this agenda item from further discussion since it is already an agenda item for the Legislative Committee.

Mr. Dryden informed the committee of educational materials that have been made available by the Division of Public health regarding Naloxone administration guidelines. Mr. Dryden will provide pharmacies within the state this information.

The committee began a discussion regarding Collaborative Care. The committee discussion ended with the consensus that the Board of Pharmacy is not the primary stake holder for this issue. Therefore this topic was requested to be removed from the agenda as well.

A motion was made to collapse the committee by Ms. Esposito and seconded by Mr. Shanehsaz. The motion carried.

#### **PUBLIC COMMENT**

None

#### **NEXT SCHEDULED MEETING**

There being no further business for the committee, there is no future meeting scheduled at this time.

#### **ADJOURNMENT**

There being no other business before the committee. A motion to adjourn was made by Ms. Esposito, seconded by Ms. Martini. The motion unanimously carried at 9:10 am.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Mast", written in a cursive style.

Christine Mast  
Administrative Specialist III  
Board of Pharmacy